An antibiotic-responsive mouse model of fulminant ulcerative colitis

PLoS Medicine

Volumn 5, Issue 3, 2008, Pages 0424-0439

  Kang, Silvia S ^a   Bloom, Seth M ^a   Norian, Lyse A ^a   Geske, Michael J ^a   Flavell, Richard A ^b   Stappenbeck, Thaddeus S ^a   Allen, Paul M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; INTERLEUKIN 10; METRONIDAZOLE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIINFECTIVE AGENT; AUTACOID; HOMEODOMAIN PROTEIN; INTERLEUKIN 10 RECEPTOR; PROTEIN SERINE THREONINE KINASE; RAG 1 PROTEIN; RAG-1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; IMMUNOREGULATION; INTESTINE FLORA; LAMINA PROPRIA; LYMPHOID TISSUE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; REPRODUCIBILITY; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; ULCERATIVE COLITIS; ANIMAL; BLOOD; C57BL MOUSE; CD4+ T LYMPHOCYTE; CYTOLOGY; DISEASE MODEL; FAILURE TO THRIVE; HUMAN; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE MUTANT; PATHOLOGY; SERODIAGNOSIS; SURVIVAL RATE; WEIGHT REDUCTION;

ANIMALS; ANTI-BACTERIAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; COLITIS, ULCERATIVE; DISEASE MODELS, ANIMAL; FAILURE TO THRIVE; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTRALIZATION TESTS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, INTERLEUKIN-10; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT LOSS;

EID: 41549111071     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0050041     Document Type: Article

References (69)

1. Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434.
2. Elson CO, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG, et al. (2005) Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 206: 260-276.
3. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, et al. (1993) Ulcerative colitis-like disease inmicewitha disrupted interleukin-2 gene. Cell 75: 253-261.
4. Rudolph U, Finegold MJ, Rich SS, Harriman GR, Srinivasan Y, et al. (1995) Ulcerative colitis and adenocarcinoma of the colon in G alpha i2-deficient mice. Nat Genet 10: 143-150.
5. Mombaerts P, Clarke AR, Rudnicki MA, Iacomini J, Itohara S, et al. (1992) Mutations in T-cell antigen receptor genes alpha and beta block thymocyte development at different stages. Nature 360: 225-231.
6. Strober W, Fuss IJ, Blumberg RS (2002) The immunology of mucosal models of inflammation. Annu Rev Immunol 20: 495-549.
7. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274.
8. Gorelik L, Flavell RA (2000) Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12: 171-181.
9. Spencer SD, Di Marco F, Hooley J, Pitts-Meek S, Bauer M, et al. (1998) The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med 187: 571-578.
10. Farmer MA, Sundberg JP, Bristol IJ, Churchill GA, Li R, et al. (2001) A major quantitative trait locus on chromosome 3 controls colitis severity in IL-10-deficient mice. Proc Natl Acad Sci U S A 98: 13820-13825.
11. Bristol IJ, Farmer MA, Cong Y, Zheng XX, Strom TB, et al. (2000) Heritable susceptibility for colitis in mice induced by IL-10 deficiency. Inflamm Bowel Dis 6: 290-302.
12. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683-765.
13. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147: 3815-3822.
14. Corinti S, Albanesi C, la Sala A, Pastore S, Girolomoni G (2001) Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol 166: 4312-4318.
15. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, et al. (1998) Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 101: 890-898.
16. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA (2006) Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24: 99-146.
17. Schreiber RD, Hicks LJ, Celada A, Buchmeier NA, Gray PW (1985) Monoclonal antibodies to murine gamma-interferon which differentially modulate macrophage activation and antiviral activity. J Immunol 134: 1609-1618.
18. Sheehan KC, Ruddle NH, Schreiber RD (1989) Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J Immunol 142: 3884-3893.
19. Ahmed AO, van Vianen W, ten Kate MT, van de Sande WW, van Belkum A, et al. (2003) A murine model of Madurella mycetomatis eumycetoma. FEMS Immunol Med Microbiol 37: 29-36.
20. Roach PD, Wallis PM, Olson ME (1988) The use of metronidazole, tinidazole and dimetridazole in eliminating trichomonads from laboratory mice. Lab Anim 22: 361-364.
21. Rath HC, Schultz M, Freitag R, Dieleman LA, Li F, et al. (2001) Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 69: 2277-2285.
22. Pull SL, Doherty JM, Mills JC, Gordon JI, Stappenbeck TS (2005) Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci U S A 102: 99-104.
23. Rosai J (1996) Gastrointestinal tract. Ackerman's Surgical Pathology. St. Louis: Mosby-Year Book Inc.
24. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, et al. (1996) Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157: 1261-1270.
25. Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, et al. (1997) A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 159: 6276-6282.
26. Papadakis KA, Targan SR (2000) Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 51: 289-298.
27. Leach MW, Bean AG, Mauze S, Coffman RL, Powrie F (1996) Inflammatory bowel disease in C.B-17 scid mice reconstituted with the CD45RBhigh subset of CD4+ T cells. Am J Pathol 148: 1503-1515.
28. Horwitz BH (2007) The straw that stirs the drink: insight into the pathogenesis of inflammatory bowel disease revealed through the study of microflora-induced inflammation in genetically modified mice. Inflamm Bowel Dis 13: 490-500.
29. Palmer C, Bik EM, Digiulio DB, Relman DA, Brown PO (2007) Development of the human infant intestinal microbiota. PLoS Biol 5: e177. doi: 10.1371/journal.pbio.0050177
30. Perencevich M, Burakoff R (2006) Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 12: 651-664.
31. Fahlen L, Read S, Gorelik L, Hurst SD, Coffman RL, et al. (2005) T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. J Exp Med 201: 737-746.
32. Asseman C, Read S, Powrie F (2003) Colitogenic Th1 cells are present in the antigen-experienced T cell pool in normal mice: control by CD4+ regulatory T cells and IL-10. J Immunol 171: 971-978.
33. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, Barbosa TC, Cumano A, et al. (2001) CD25+ CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol 166: 3008-3018.
34. Uhlig HH, Coombes J, Mottet C, Izcue A, Thompson C, et al. (2006) Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol 177: 5852-5860.
35. Fuss IJ, Boirivant M, Lacy B, Strober W (2002) The interrelated roles of TGF-beta and IL-10 in the regulation of experimental colitis. J Immunol 168: 900-908.
36. Li MO, Sanjabi S, Flavell RA (2006) Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25: 455-471.
37. Marie JC, Liggitt D, Rudensky AY (2006) Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity 25: 441-454.
38. Powrie F (1995) T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity 3: 171-174.
39. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, et al. (1997) A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389: 737-742.
40. Levings MK, Gregori S, Tresoldi E, Cazzaniga S, Bonini C, et al. (2005) Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 105: 1162-1169.
41. Chen ZM, O'Shaughnessy MJ, Gramaglia I, Panoskaltsis-Mortari A, Murphy WJ, et al. (2003) IL-10 and TGF-beta induce alloreactive CD4+CD25- T cells to acquire regulatory cell function. Blood 101: 5076-5083.
42. Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, et al. (2002) In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 195: 603-616.
43. Madsen KL, Lewis SA, Tavernini MM, Hibbard J, Fedorak RN (1997) Interleukin 10 prevents cytokine-induced disruption of T84 monolayer barrier integrity and limits chloride secretion. Gastroenterology 113: 151-159.
44. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, et al. (2004) Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 22: 929-979.
45. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, et al. (2006) IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 290: G827-G838.
46. Nagalakshmi ML, Rascle A, Zurawski S, Menon S, de Waal Malefyt R (2004) Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int Immunopharmacol 4: 679-691.
47. Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, et al. (2005) Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 129: 969-984.
48. Baumgart DC, Sandborn WJ (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369: 1641-1657.
49. Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, et al. (1994) Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1: 553-562.
50. Kojouharoff G, Hans W, Obermeier F, Mannel DN, Andus T, et al. (1997) Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 107: 353-358.
51. Kullberg MC, Ward JM, Gorelick PL, Caspar P, Hieny S, et al. (1998) Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism. Infect Immun 66: 5157-5166.
52. Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, et al. (1996) Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 98: 1010-1020.
53. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, et al. (2003) Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
54. Uhlig HH, McKenzie BS, Hue S, Thompson C, Joyce-Shaikh B, et al. (2006) Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 25: 309-318.
55. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, et al. (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13: 715-725.
56. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, et al. (2004) Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351: 2069-2079.
57. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W (1995) Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182: 1281-1290.
58. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, et al. (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314: 1461-1463.
59. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, et al. (2006) IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116: 1310-1316.
60. Kullberg MC, Jankovic D, Feng CG, Hue S, Gorelick PL, et al. (2006) IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med 203: 2485-2494.
61. Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, et al. (2006) Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 203: 2473-2483.
62. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, et al. (1998) Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 66: 5224-5231.
63. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R (2004) Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118: 229-241.
64. Habtezion A, Toivola DM, Butcher EC, Omary MB (2005) Keratin-8-deficient mice develop chronic spontaneous Th2 colitis amenable to antibiotic treatment. J Cell Sci 118: 1971-1980.
65. Hoentjen F, Harmsen HJ, Braat H, Torrice CD, Mann BA, et al. (2003) Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice. Gut 52: 1721-1727.
66. Sartor RB (2003) Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when. Curr Opin Gastroenterol 19: 358-365.
67. Gionchetti P, Rizzello F, Lammers KM, Morselli C, Tambasco R, et al. (2006) Antimicrobials in the management of inflammatory bowel disease. Digestion 73 Suppl 1: 77-85.
68. Cuffari C, Present DH, Bayless TM, Lichtenstein GR (2005) Optimizing therapy in patients with pancolitis. Inflamm Bowel Dis 11: 937-946.
69. Ho G, Lees C, Satsangi J (2007) Ulcerative colitis. Medicine 35: 277-282.